article thumbnail

Biogen strikes RNAi deal with City; Aurion withdraws IPO

BioPharma Drive: Drug Pricing

Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug. City will receive $46 million from Biogen under the alliance.

Licensing 180
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Drugs 156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK-licensed antibiotic meets goal in late-stage study

BioPharma Drive: Drug Pricing

The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under development by Spero.

Licensing 255
article thumbnail

Tofersen

New Drug Approvals

4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] Jump up to: a b c d e f g h i j k l “FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene” (Press release). Food and Drug Administration (FDA). 3 November 2006. 3 June 2024.

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. You can unsubscribe at anytime. Drugmakers are working to coopt this process with targeted therapies.

article thumbnail

Biotech leader champions targeted cancer treatments and diversity

Drug Target Review

I saw an opportunity which others didn’t, to develop a small molecule targeting a well-known cancer pathway, a master switch of cancer Afterwards, I moved to Germany to work for Merck KGaA, where I headed up the licensing and business development team. I would also advise anyone, young women and men included, to always believe in themselves.

article thumbnail

Gepirone

New Drug Approvals

4] This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness. [5] 5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] It is taken orally. [1]

FDA 62